Posted by Michael Wonder on 22 May 2018
Janssen questions literature review on biosimilar switching studies as authors defend it
22 May 2018 - Three employees of Johnson & Johnson’s Janssen Pharmaceuticals, which has not publicly disclosed that it is developing any biosimilars, urged caution Tuesday on a literature review of biosimilar switching studies and said additional studies are necessary, though authors of the review also pushed back.
The letter to editor from Janssen’s Antonio Pires, integrated evidence team leader, Kavitha Goyal, senior director for Remicade development, and Andrew Greenspan, VP of medical affairs, follow a push from their parent company to protect its multi-billion dollar biologic Remicade (infliximab) from further competition.
Pfizer in December won approval for its second Remicade biosimilar, and Pfizer and J&J are locked in a legal debate as Pfizer claims “J&J's exclusionary plan has been remarkably effective at stifling competition.”
